NEW YORK, July 17, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of the issuance of patent number 2011127184 in Russia. This patent is in the family titled "Compositions and Methods of Vascular Injury Repair" and protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI").
"This incremental patent brings AMR-001's total worldwide patent coverage to eleven patents, and offers AMR-001 product protection in this important geography," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. According to reports, cardiovascular disease accounts for 57% of all deaths in Russia, or approximately 1 million deaths per year, with a total economic cost corresponding to 3 percent of the country's GDP for the period of 2006-2009. Psychosocial factors, high alcohol intake, tobacco smoking, eating habits, hypertension, physical inactivity, and obesity are all significant contributing risk factors in Russia, a country with a population of roughly 143 million.
"We look forward to further expansion of our intellectual property in the coming years, both in the United States and abroad, in parallel with the clinical development of AMR-001," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "The Company is on track to complete enrollment this year in the Phase 2 PreSERVE AMR-001 clinical trial to investigate the preservation of heart function after certain severe heart attacks and expects to have the first data readout available six to eight months after the last patient is enrolled."NeoStem's AMR-001 is a cell therapy in development for the treatment of cardiovascular disease. If approved by the U.S. Food and Drug Administration and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI and position the Company to capture a meaningful share of the worldwide AMI market.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV